|
시장보고서
상품코드
2106668
인공 심박동기 : 시장 인사이트, 경쟁 구도 및 시장 예측(-2034년)Pacemakers - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 인공 심박동기 시장은 2025년에 64억 9,000만 달러로 추산되며, 2034년까지 105억 1,000만 달러에 달할 것으로 예측됩니다. 이러한 성장의 배경에는 심혈관 질환 및 서맥성 부정맥으로 인한 전 세계적 부담 증가, 고령 인구 확대, 그리고 리드리스형 및 MRI 호환형 인공 심박동기 플랫폼의 도입 가속화가 있습니다.
- 전 세계 인공 심박동기 시장은 2026년부터 2034년까지의 예측 기간 동안 연평균 성장률(CAGR) 5.5%로 성장하고 있습니다.
- 이식 가능성에 따라 보면, 2025년 시점에서 광범위한 이식형 인공 심박동기 카테고리 중 듀얼 챔버 인공 심박동기 부문이 52%의 점유율을 차지하며 인공 심박동기 시장을 주도했습니다.
- 기기 유형별로는 2025년 MRI 호환형 인공 심박동기 부문이 84%의 점유율로 인공 심박동기 시장을 주도했으나, 리드리스형 MRI 호환 인공 심박동기가 가장 빠른 성장세를 기록했습니다.
- 최종 사용자별로는 2025년에 병원 부문이 64%의 점유율을 차지하며 인공 심박동기 시장을 주도했습니다.
- 2025년, 북미는 전 세계 인공 심박동기 시장 매출의 44%를 차지하며 전 세계적으로 가장 높은 지역별 시장 점유율을 기록했습니다.
인공 심박동기는 일반적으로 쇄골 부근 피하에 이식되는 배터리 구동식 소형 의료기기로, 서맥, 심장 차단 또는 관련 전도 장애가 있는 환자의 비정상적인 심장 박동 리듬을 조절하기 위해 전기 자극을 전달합니다. 최신 시스템은 기존의 단실형 및 이실형 경정맥형 기기에서 양심실형/심장 재동기화 치료(CRT)(CRT) 인공 심박동기, 그리고 최근에는 카테터를 이용해 심강 내에 직접 이식되는 리드리스형 기기에 이르기까지 다양합니다. 시장은 이식형 인공 심박동기의 이식 방식에 따라 분류되며, 나아가 단실형, 이실형, 양심실형/CRT 인공 심박동기, 그리고 급성 또는 일과성 적응증에 사용되는 외부(일시적) 인공 심박동기로 세분화됩니다. 또한, 기기 유형별로는 MRI 호환형 및 리드리스형 MRI 호환 인공 심박동기로 분류되며, 최종 사용자별로는 병원, 외래수술센터(ASC), 기타 의료 현장으로 분류됩니다. 고령화의 진행, 부정맥 및 심부전의 유병률 상승, 배터리 수명 연장, 소형화, MRI 호환성, 전도계 페이싱 분야의 지속적인 기술 혁신, 그리고 원격 모니터링 기능 확충에 힘입어, 인공 심박동기는 전 세계 심장 리듬 관리 기기 산업에서 핵심 분야이며, 꾸준히 성장을 이어가고 있는 카테고리입니다.
인공 심박동기 시장의 주요 성장 촉진요인
- 심혈관 질환 및 서맥성 부정맥으로 인한 전 세계적 부담이 증가함에 따라 이식 건수가 확대되고 있습니다. 심장 및 순환기 질환은 전 세계적으로 약 5억 5,000만 명에게 영향을 미치고 있으며, 관상동맥 질환만으로도 2억 4,400만 명 이상에게 영향을 주고 있습니다.
- 고령 인구 증가는 구조적인 호재로 작용하고 있으며, WHO의 예측에 따르면 60세 이상 인구는 2050년까지 약 2배인 21억 명에 달하고, 80세 이상 인구는 같은 기간 동안 3배 가까이 증가할 것으로 전망됩니다.
- 메드트로닉(Medtronic)사의 ‘Micra AV2/VR2’와 애보트(Abbott)사의 ‘Aveir VR/DR’ 시스템을 비롯한 리드리스 인공 심박동기의 임상 현장에서의 급속한 보급으로 인해, 경정맥 리드가 불필요해지고 감염증 및 리드 고장의 위험이 감소함에 따라 대상 환자층이 확대되고 있습니다.
- MRI 대응 플랫폼, 전도계 및 좌측 다발 분지 영역 페이싱(LBBAP), 자동 원격 모니터링, 배터리 수명 연장 등 지속적인 기술 혁신을 통해 임상 적응증과 교체 주기가 확대되고 있습니다.
- 보스턴 사이언티피크가 2024년부터 2025년에 걸쳐 전도계 페이싱용 ‘INGEVITY+’ 페이싱 리드의 FDA 및 CE 마크 적응증 확대, 바이오트로닉의 2026년 'Solia CSP S' 리드에 대한 FDA 승인 등 규제 당국의 승인 및 적응증 확대로 인해 생리적 페이싱의 기회가 확대되고 있습니다.
- 마이크로포트 사이언티픽이 2025년 중국 시장을 대상으로 TEN 인공 심박동기 제품군을 현지화하여 출시하는 등, 아시아태평양을 거점으로 하는 경쟁사들의 제조 및 판매 거점 확대는 고성장을 이루고 있는 신흥 시장에서의 접근성 향상과 가격 경쟁력을 촉진하고 있습니다.
- 선진국 및 신흥 시장의 보험 급여 제도 개선과 심혈관 질환에 대한 인식 제고가 맞물려, 2034년까지 시장은 안정적인 한 자릿수 중반대의 성장세를 유지할 것으로 예측됩니다.
인공 심박동기 시장 성장에 기여하는 요인
시장 성장 촉진요인
심혈관 질환 및 서맥성 부정맥 유병률 증가
인공 심박동기 시장의 가장 큰 촉진요인은 심혈관 질환, 부정맥 및 전도 장애로 인한 전 세계적 부담 증가입니다. 2020년에는 전 세계적으로 약 2억 4,400만 명이 관상동맥 질환을 앓고 있었으며, 심장 및 순환기 질환은 여성 약 2억 9,000만 명, 남성 약 2억 6,000만 명을 포함해 전 세계적으로 약 5억 5,000만 명에게 영향을 미치고 있습니다. 심방세동, 동맥부전 증후군, 고도 방실 차단은 노화에 따라 유병률이 높아지기 때문에 영구형 인공 심박동기를 통한 서맥 지원이 필요한 환자층은 계속해서 확대되고 있습니다. 인공 심박동기 이식은 확립된 지침에 기반한 치료법이며, 장기적인 치료 성과에 관한 확실한 데이터도 존재하기 때문에 질환 발생률의 상승은 직접적이고 예측 가능한 형태로 시술 건수 증가로 이어져, 2034년까지 시장 성장을 뒷받침하는 요인이 될 것입니다.
고령 인구 확대
세계 인구의 급속한 고령화는 인공 심박동기 수요에 있어 구조적인 호재로 작용하고 있습니다. 이는 서맥성 부정맥이나 전도계 질환이 고령자에게 특히 많이 나타나기 때문입니다. 세계보건기구(WHO)의 추산에 따르면, 2020년 60세 이상 인구는 약 10억 명이었으나, 이 수치는 2050년까지 약 21억 명으로 거의 두 배로 증가할 것으로 예측됩니다. 한편, 80세 이상 인구는 같은 기간 동안 약 4억 2,600만 명으로 3배 가까이 증가할 것으로 전망됩니다. 북미, 유럽, 그리고 점점 더 아시아태평양에서 이러한 인구 동태의 변화가 진행됨에 따라, 최초 이식이나 기기 교체의 대상이 되는 환자 기반도 그에 따라 확대되어, 기존의 인공 심박동기 시스템과 리드리스 인공 심박동기 시스템 모두에 대한 장기적인 수요가 유지될 것입니다.
시장 성장 억제요인
견고한 기초 수요가 있음에도 불구하고, 인공 심박동기 시장은 중대한 제약에 직면해 있습니다. 첨단 인공 심박동기 시스템, 특히 리드리스형이나 MRI 대응형 플랫폼의 고액 초기 비용은 가격에 민감한 시장이나 신흥 시장에서 구매 장벽이 되어, 보험 환급에 의존하는 도입을 제한하고 있습니다. 배터리 성능, 리드 절연 불량 또는 소프트웨어 결함으로 인한 기기 리콜이나 안전 관련 현장 조치는 의사와 환자의 신뢰를 훼손하고, 막대한 비용이 소요되는 시정 조치를 초래할 가능성이 있습니다. 지역별로 장기간에 걸쳐 불균일한 규제 승인 절차가 존재하며, 특히 새로운 리드리스형이나 전도계 페이싱 플랫폼의 경우 시장 출시까지의 기간을 연장하고 개발 비용을 상승시키고 있습니다. 일부 신흥 시장에서는 훈련을 받은 전기생리학자나 심장 임플란트 전문의가 부족하여, 기기를 구할 수 있더라도 시술 건수가 제한되고 있습니다. 기존의 경정맥형 시스템에 수반되는 감염, 리드 이탈, 포켓 침식 등의 이식 후 합병증은 일부 환자와 의료 제공업체의 선택에 계속해서 영향을 미치고 있습니다. 지역별로 상이한 보험 환급 제도와 본인 부담금에 더해, 아시아태평양의 현지 저비용 제조업체들로부터의 가격 압박까지 겹치면서, 예측 기간 동안 판매 대수는 계속 증가할 것으로 보이지만 시장 가치 전체의 성장세는 더욱 둔화되고 있습니다.
자주 묻는 질문
목차
제1장 인공 심박동기 시장 보고서 도입
제2장 인공 심박동기 시장 주요 요약
제3장 인공 심박동기 시장의 주요 요인 분석
제4장 영향 분석 : AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 인공 심박동기 시장 : Porter의 Five Forces 분석
제7장 인공 심박동기 시장 평가
제8장 인공 심박동기 시장 경쟁 구도
제9장 인공 심박동기 시장 스타트업의 자금조달 및 투자 동향
제10장 인공 심박동기 시장 : 기업 개요 및 제품 개요
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSH 26.08.12Pacemakers Market Summary
Overview:
- The Pacemakers market is estimated at USD 6.49 billion in 2025 and is projected to reach USD 10.51 billion by 2034. Growth is anchored in the rising global burden of cardiovascular disease and bradyarrhythmia, an expanding geriatric population, and accelerating adoption of leadless and MRI-conditional pacing platforms.
- The global Pacemakers market is growing at a CAGR of 5.5% during the forecast period from 2026 to 2034.
- By implantability, the dual-chamber pacemaker segment dominated the Pacemakers market with a 52% share in 2025, within the broader implantable pacemaker category.
- By device type, the MRI-compatible pacemaker segment dominated the Pacemakers market with an 84% share in 2025, while leadless MRI-compatible pacemakers posted the fastest growth.
- By end-user, the hospitals segment dominated the Pacemakers market with a 64% share in 2025.
- North America dominated the global Pacemakers market revenue with a 44% share in 2025, representing the highest regional market share globally.
A pacemaker is a small, battery-powered medical device implanted under the skin, typically near the collarbone, that delivers electrical impulses to regulate an abnormal heart rhythm in patients with bradycardia, heart block, or related conduction disorders. Modern systems range from conventional single- and dual-chamber transvenous devices to biventricular/cardiac resynchronization therapy pacemakers and, most recently, catheter-delivered leadless devices implanted directly within a heart chamber. The market is organized by implantability across implantable pacemakers, further split into single-chamber, dual-chamber, and biventricular/CRT pacemakers, and external (temporary) pacemakers used for acute or transient indications; by device type across MRI-compatible and leadless MRI-compatible pacemakers; and by end-user across hospitals, ambulatory surgical centres, and other care settings. Driven by an aging population, rising prevalence of arrhythmias and heart failure, continuous innovation in battery longevity, miniaturization, MRI conditionality, and conduction system pacing, and expanding remote-monitoring connectivity, pacemakers remain a foundational and steadily growing category within the global cardiac rhythm management device industry.
Pacemakers Market Key Growth Drivers
- The rising global burden of cardiovascular disease and bradyarrhythmia is expanding implant volumes, with heart and circulatory disease affecting an estimated 550 million people worldwide and coronary heart disease alone affecting over 244 million people.
- The growing geriatric population is a structural tailwind, with the WHO projecting the number of people aged 60 and above to roughly double to 2.1 billion by 2050 and those aged 80 and above to nearly triple over the same period.
- Rapid clinical adoption of leadless pacemakers, including Medtronic's Micra AV2/VR2 and Abbott's Aveir VR/DR systems, is expanding the addressable patient pool by eliminating transvenous leads and reducing infection and lead-failure risk.
- Continuous technological innovation, including MRI-conditional platforms, conduction system and left bundle branch area pacing (LBBAP), automated remote monitoring, and longer battery life, is broadening clinical indications and replacement cycles.
- Regulatory approvals and label expansions, such as Boston Scientific's 2024-2025 FDA and CE Mark expansions of INGEVITY+ pacing leads for conduction system pacing and Biotronik's 2026 FDA approval of the Solia CSP S lead, are widening the physiological pacing opportunity.
- Expanding manufacturing and commercial footprints among Asia-Pacific-based competitors, including MicroPort Scientific's 2025 localized TEN pacemaker family launch in China, are improving access and affordability in high-growth emerging markets.
- Improving reimbursement frameworks and rising cardiovascular-disease awareness across developed and emerging markets are together expected to sustain steady, mid-single-digit growth in the market through 2034.
Key Companies in Pacemakers Market
The competitive landscape is led by the following active device manufacturers:
- Medtronic, Inc.
- St. Jude Medical, Inc.
- Boston Scientific Corporation
- Biotronik SE & Co. KG
- LivaNova PLC
- Shree Pacetronix Ltd.
- OSCOR Inc.
- MEDICO S.p.A.
- Lepu Medical Technology Co. Ltd.
- MicroPort Scientific Corporation
Factors Contributing to the Growth of the Pacemakers Market
Market Drivers
Rising Prevalence of Cardiovascular Diseases and Bradyarrhythmia
The single most powerful driver of the Pacemakers market is the growing global burden of cardiovascular disease, arrhythmias, and conduction disorders. Coronary heart disease affected an estimated 244 million people worldwide in 2020, and heart and circulatory diseases collectively affect approximately 550 million people globally, including roughly 290 million women and 260 million men. As atrial fibrillation, sick sinus syndrome, and high-grade atrioventricular block become more prevalent with age, the pool of patients requiring bradycardia support through permanent pacing continues to expand. Because pacemaker implantation is a well-established, guideline-directed therapy with strong long-term outcomes data, rising disease incidence translates directly and predictably into growing procedure volumes, anchoring market growth through 2034.
Expanding Geriatric Population
The rapidly aging global population is a structural tailwind for pacemaker demand, since bradyarrhythmia and conduction system disease disproportionately affect older adults. The World Health Organization estimated that around one billion people were aged 60 or older in 2020, a figure projected to roughly double to approximately 2.1 billion by 2050, while the population aged 80 and above is expected to nearly triple over the same period to about 426 million. As this demographic shift unfolds across North America, Europe, and increasingly Asia-Pacific, the underlying patient base eligible for first-time implantation and device replacement expands correspondingly, sustaining long-run demand for both conventional and leadless pacing systems.
Market Restraints
Despite steady underlying demand, the Pacemakers market faces material constraints. The high upfront cost of advanced pacemaker systems, particularly leadless and MRI-conditional platforms, limits affordability and reimbursement-driven adoption in price-sensitive and emerging markets. Device recalls and safety-related field actions tied to battery performance, lead insulation failure, or software malfunction can erode physician and patient confidence and trigger costly corrective actions. Lengthy and heterogeneous regulatory pathways across geographies, particularly for novel leadless and conduction-system-pacing platforms, extend time to market and raise development costs. A shortage of trained electrophysiologists and cardiac implant specialists in several emerging markets constrains procedure volumes even where device access exists. Post-implantation complications, including infection, lead dislodgement, and pocket erosion associated with conventional transvenous systems, continue to weigh on some patient and provider preferences. Uneven reimbursement and out-of-pocket cost burden across geographies, together with pricing pressure from local low-cost manufacturers in Asia-Pacific, further tempers overall market value growth, even as unit volumes continue to expand across the forecast period.
Pacemakers Market Segment Analysis
The pacemakers market by implantability (implantable pacemaker [single-chamber pacemaker, dual-chamber pacemaker, and biventricular/CRT pacemaker], and external pacemaker), device type (MRI-compatible pacemaker and leadless MRI-compatible pacemaker), end-user (hospitals, ambulatory surgical centres, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Implantability
Dominant Subsegment: Dual-Chamber Pacemaker.
Dominant: Dual-Chamber Pacemaker ~ 52%
The dual-chamber pacemaker segment accounted for approximately 52% of the Pacemakers market in 2025, within the broader implantable pacemaker category, which itself represents roughly 86% of total market value. Dual-chamber (DDD) systems use separate leads in the right atrium and right ventricle, sensing intrinsic electrical activity in each chamber and preserving atrioventricular synchrony, which more closely mimics natural cardiac physiology than single-chamber pacing. This synchrony reduces the risk of pacemaker syndrome and atrial fibrillation, improves symptoms of heart failure, and modestly improves quality of life relative to ventricular-only pacing, making dual-chamber devices the default choice across most sinus node dysfunction and AV block indications. Single-chamber pacemakers retain a meaningful share in patients with permanent atrial fibrillation or isolated ventricular pacing needs, while biventricular/CRT pacemakers, though a smaller share, are growing steadily on the back of expanding heart-failure indications. External (temporary) pacemakers serve acute, transient bradycardia needs in critical-care and peri-procedural settings and represent the remainder of the implantability segment. While leadless and CRT platforms are growing fastest, the clinical breadth and procedural familiarity of dual-chamber pacing secure its leadership across the forecast period.
By Device Type
Dominant Subsegment: MRI Compatible Pacemaker.
Dominant: MRI Compatible Pacemaker ~ 84%
The MRI compatible pacemaker segment accounted for approximately 84% of the Pacemakers market in 2025. Conventional transvenous MRI-conditional systems, such as Biotronik's Entovis and Amvia Edge families, Medtronic's Azure XT DR MRI SureScan platform, Boston Scientific's Accolade MRI, and Abbott's Assurity MRI, remain the default choice for most first-time implants because they are compatible with the widest range of pacing indications, offer the deepest base of long-term clinical evidence, and are broadly reimbursed across major markets. MRI conditionality itself has become a near-standard feature rather than a premium add-on, reflecting the clinical need for patients to safely access diagnostic MRI scans without pre- or post-scan reprogramming. Leadless MRI compatible pacemakers, led by Medtronic's Micra AV2/VR2 and Abbott's Aveir VR/DR platforms, represent the fastest-growing device type as physician experience broadens and dual-chamber leadless synchronization technology matures, but their share remains constrained by higher unit costs, narrower indication profiles, and the need for specialized catheter-based implantation skills. The combination of established clinical evidence, broad indication coverage, and near-universal reimbursement secures the leadership of MRI-compatible transvenous pacemakers through 2034.
Pacemakers Market Region Analysis
Dominant Region: North America
North America accounted for 44% of the global Pacemakers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a well-established cardiac care infrastructure, a large and aging population with a high prevalence of cardiovascular disease, favorable and predictable reimbursement frameworks, and rapid adoption of premium technologies such as leadless and MRI-conditional pacemakers. The United States Centers for Disease Control and Prevention estimated that about 20.1 million American adults aged 20 and older had coronary artery disease in 2020, and that someone in the country experiences a heart attack roughly every 40 seconds. A dense concentration of leading manufacturers, including Medtronic, Boston Scientific, and Abbott, together with steady FDA approvals of next-generation leadless and conduction-system-pacing devices, reinforces the region's technology leadership and continued market share through the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Pacemakers market. The region's elevated CAGR is driven by rising cardiovascular disease incidence, expanding hospital-based cardiac care infrastructure, growing government healthcare investment, and the localization of manufacturing by both global and domestic players across China, Japan, India, South Korea, and Australia. MicroPort Scientific Corporation's March 2025 launch of its localized TEN pacemaker family in China illustrates the region's shift toward affordable, domestically manufactured devices tailored to local regulatory and clinical needs. China's expanding cardiac catheterization capacity, Japan's aging population and steady technology adoption, and India's growing private hospital network are collectively accelerating implant volumes. The combination of rising disease burden, improving reimbursement access, and local manufacturing scale-up positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global Pacemakers market revenue in 2025. The United States dominates on the strength of its cardiac care infrastructure, high cardiovascular disease burden, favorable reimbursement, and the concentrated presence of leading global manufacturers, while steady regulatory approvals of leadless and conduction-system-pacing technologies reinforce the region's continued technology leadership.
Europe
Europe is a large and technologically advanced regional market, supported by established CE Mark regulatory pathways, strong national reimbursement systems, and a deep base of cardiac rhythm management expertise anchored by manufacturers such as Biotronik and, historically, LivaNova's cardiac rhythm management heritage before its 2018 divestment to MicroPort. Regulatory momentum, including Boston Scientific's 2025 CE Mark expansion for conduction system pacing indications, reinforces the region's role as an early-adoption market for physiological pacing technologies across Germany, France, the United Kingdom, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease incidence, expanding hospital infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. MicroPort Scientific's localized device launches in China, Lepu Medical's expanding domestic device portfolio, and Japan's steady adoption of advanced leadless technology are accelerating regional growth and narrowing the historical technology-access gap with North America and Europe.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac care infrastructure, rising diagnosis rates for arrhythmias and conduction disorders, and gradual improvement in reimbursement and insurance coverage are broadening access, while international partnerships and technology-transfer arrangements support the gradual build-out of regional implantation capacity.
Pacemakers Market Competitive Landscape
The Pacemakers market is classified as Moderately Consolidated. A group of large, diversified medical technology leaders, including Medtronic, Boston Scientific, and Biotronik, anchor the top tier through broad product portfolios, deep clinical evidence, and global commercial reach, while specialized and regional manufacturers such as Shree Pacetronix, OSCOR, MEDICO S.p.A., Lepu Medical Technology, and MicroPort Scientific compete through focused product lines, competitive pricing, and strong positions in domestic or niche markets, increasing competitive intensity in price-sensitive and fast-growing geographies.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately consolidated, with a small number of global leaders anchoring premium technology segments and a broader field of regional and specialized manufacturers competing on price and local access.
- Leading players: Medtronic, Boston Scientific, and Biotronik anchor the top tier through leadless pacing, conduction-system-pacing, and MRI-conditional technology leadership.
- Geographic reach: Leading players operate global commercial and manufacturing networks, while companies such as MicroPort Scientific and Lepu Medical concentrate strength in China and broader Asia-Pacific markets.
- Product portfolio strength: Top players offer end-to-end pacing portfolios spanning single- and dual-chamber, biventricular/CRT, and leadless systems, complemented by dedicated conduction-system-pacing leads.
- Technology access: Leadership in leadless pacing, MRI conditionality, and conduction system/LBBAP pacing, including proprietary technologies such as Medtronic's Micra platform and Biotronik's Solia CSP S lead, is a decisive competitive advantage.
- Strategic partnerships: Regional joint ventures and licensing arrangements, such as the historical LivaNova-MicroPort cardiac rhythm management transaction and MicroPort's China-focused affiliate structure, extend market reach.
- M&A and portfolio activity: Ongoing portfolio realignment, including MicroPort CardioFlow's 2025 merger with MicroPort CRM to build an integrated cardiac diagnosis and therapy platform, reflects active consolidation within the broader cardiac rhythm management space.
- Manufacturing capabilities: Automated, high-precision manufacturing of miniaturized pulse generators and pacing leads, together with rigorous quality and reliability testing, forms a key competitive moat.
- Innovation focus: Leadless and dual-chamber leadless pacing, conduction system pacing (LBBAP), extended battery longevity, MRI conditionality, and remote-monitoring connectivity define the current innovation frontier.
Pacemakers Market Recent Developmental Activities
In 2026, Biotronik SE & Co. KG received FDA approval for its Solia CSP S pacing lead, purpose-built for left bundle branch area pacing (LBBAP), combining a stylet-driven lead platform with a newly designed fixed helix. Strategic significance: Reinforces Biotronik's leadership in physiological, conduction-system pacing technology.
In December 2025, MicroPort Scientific Corporation announced that its subsidiary MicroPort CardioFlow's strategic merger with MicroPort Cardiac Rhythm Management, structured as a share-based transaction valued at approximately USD 680 million, was approved by shareholders. Strategic significance: Builds an integrated structural heart, rhythm management, and heart failure platform.
Pacemakers Market Segmentation
Pacemakers Market by Implantability
- Implantable Pacemaker
- Single-Chamber Pacemaker
- Dual-Chamber Pacemaker
- Biventricular/CRT Pacemaker
- External Pacemaker
Pacemakers Market by Device Type
- MRI Compatible Pacemaker
- Leadless MRI Compatible Pacemaker
Pacemakers Market by End User
- Hospitals
- Ambulatory Surgical Centers
- Others
Pacemakers Market by Geography
- North America Pacemakers Market
- United States Pacemakers Market Size in USD million (2023-2034)
- Canada Pacemakers Market Size in USD million (2023-2034)
- Mexico Pacemakers Market Size in USD million (2023-2034)
- Europe Pacemakers Market
- Germany Pacemakers Market Size in USD million (2023-2034)
- United Kingdom Pacemakers Market Size in USD million (2023-2034)
- France Pacemakers Market Size in USD million (2023-2034)
- Italy Pacemakers Market Size in USD million (2023-2034)
- Spain Pacemakers Market Size in USD million (2023-2034)
- Rest of Europe Pacemakers Market Size in USD million (2023-2034)
- Asia-Pacific Pacemakers Market
- China Pacemakers Market Size in USD million (2023-2034)
- Japan Pacemakers Market Size in USD million (2023-2034)
- India Pacemakers Market Size in USD million (2023-2034)
- Australia Pacemakers Market Size in USD million (2023-2034)
- South Korea Pacemakers Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Pacemakers Market Size in USD million (2023-2034)
- Rest of the World (RoW) Pacemakers Market
- Middle East Pacemakers Market Size in USD million (2023-2034)
- Africa Pacemakers Market Size in USD million (2023-2034)
- South America Pacemakers Market Size in USD million (2023-2034)
Key Takeaways from the Pacemakers Market Report Study
- Market size analysis for the current pacemakers market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global pacemakers market.
- Various opportunities available for competitors in the pacemakers market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current pacemakers market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for pacemakers market growth in the future?
Target audience who can benefit from this Pacemakers market report study
- Pacemakers product providers
- Research organizations and consulting companies
- Pacemakers-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in pacemakers
- Various end-users who want to know more about the pacemakers market and the latest technological developments in the pacemakers market.
Frequently Asked Questions:
Q1. What is the growth rate of the pacemakers market?
The Pacemakers market is projected to expand at a CAGR of 5.5% during the forecast period from 2026-2034.
Q2. What is the market size of the pacemakers market?
The Pacemakers market is estimated at USD 6.49 billion in 2025 and is projected to reach USD 10.51 billion by 2034.
Q3. Which region dominates the pacemakers market?
North America dominated the pacemakers market with a 44% share of global revenue in 2025, supported by a well-established cardiac care infrastructure, high cardiovascular disease prevalence, favorable reimbursement, and the concentrated presence of leading global manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Pacemakers market?
The principal drivers are the rising global prevalence of cardiovascular disease and bradyarrhythmia; the rapidly expanding geriatric population, with the WHO projecting the population aged 60 and above to roughly double to 2.1 billion by 2050; rapid adoption of leadless pacemaker technology; continuous innovation in conduction system and left bundle branch area pacing; and expanding remote-monitoring connectivity.
Q5. Who are the major players in the pacemakers market?
The major players include Medtronic, Inc., St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., and MicroPort Scientific Corporation, among other active providers profiled in the Competitive Landscape section. Medtronic, Boston Scientific, and Biotronik lead through leadless and conduction-system-pacing technology.
Table of Contents
1. Pacemakers Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Pacemakers Market Executive Summary
- 2.1 Market at a Glance
3. Pacemakers Market Key Factors Analysis
- 3.1 Pacemakers Market Drivers
- 3.1.1 Rising Prevalence of Cardiovascular Diseases and Bradyarrhythmia
- 3.1.2 Expanding Geriatric Population
- 3.1.3 Rapid Adoption of Leadless Pacemaker Technology
- 3.1.4 Continuous Technological Innovation in Pacing Therapy
- 3.2 Pacemakers Market Restraints and Challenges
- 3.2.1 High Device Cost and Reimbursement Variability
- 3.2.2 Device Recalls and Post-Implantation Complications
- 3.2.3 Regulatory Complexity and Specialist Workforce Constraints
- 3.3 Pacemakers Market Opportunities
- 3.3.1 Conduction System and Left Bundle Branch Area Pacing Expansion
- 3.3.2 Emerging-Market and Regional Manufacturing Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Pacemakers Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Pacemakers Market Assessment
- 7.1 By Implantability
- 7.1.1 Implantable Pacemaker
- 7.1.1.1 Single-Chamber Pacemaker
- 7.1.1.2 Dual-Chamber Pacemaker
- 7.1.1.3 Biventricular/CRT Pacemaker
- 7.1.2 External Pacemaker
- 7.1.1 Implantable Pacemaker
- 7.2 By Device Type
- 7.2.1 MRI Compatible Pacemaker
- 7.2.2 Leadless MRI Compatible Pacemaker
- 7.3 By End-User
- 7.3.1 Hospitals
- 7.3.2 Ambulatory Surgical Centres
- 7.3.3 Others
- 7.4 By Geography
- 7.4.1 North America
- 7.4.1.1 United States Pacemakers Market Size in USD million (2023-2034)
- 7.4.1.2 Canada Pacemakers Market Size in USD million (2023-2034)
- 7.4.1.3 Mexico Pacemakers Market Size in USD million (2023-2034)
- 7.4.2 Europe
- 7.4.2.1 Germany Pacemakers Market Size in USD million (2023-2034)
- 7.4.2.2 United Kingdom Pacemakers Market Size in USD million (2023-2034)
- 7.4.2.3 France Pacemakers Market Size in USD million (2023-2034)
- 7.4.2.4 Italy Pacemakers Market Size in USD million (2023-2034)
- 7.4.2.5 Spain Pacemakers Market Size in USD million (2023-2034)
- 7.4.2.6 Rest of Europe Pacemakers Market Size in USD million (2023-2034)
- 7.4.3 Asia-Pacific
- 7.4.3.1 China Pacemakers Market Size in USD million (2023-2034)
- 7.4.3.2 Japan Pacemakers Market Size in USD million (2023-2034)
- 7.4.3.3 India Pacemakers Market Size in USD million (2023-2034)
- 7.4.3.4 Australia Pacemakers Market Size in USD million (2023-2034)
- 7.4.3.5 South Korea Pacemakers Market Size in USD million (2023-2034)
- 7.4.3.6 Rest of Asia-Pacific Pacemakers Market Size in USD million (2023-2034)
- 7.4.4 Rest of World
- 7.4.4.1 Middle East Pacemakers Market Size in USD million (2023-2034)
- 7.4.4.2 Africa Pacemakers Market Size in USD million (2023-2034)
- 7.4.4.3 South America Pacemakers Market Size in USD million (2023-2034)
- 7.4.1 North America
8. Pacemakers Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Pacemakers Market Startup Funding and Investment Trends
10. Pacemakers Market Company and Product Profiles
- 10.1 Medtronic, Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 St. Jude Medical, Inc.
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Boston Scientific Corporation
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Biotronik SE & Co. KG
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 LivaNova PLC
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Shree Pacetronix Ltd.
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 OSCOR Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 MEDICO S.p.A.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Lepu Medical Technology Co. Ltd.
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10. 10 MicroPort Scientific Corporation
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
